Developing and updating local formularies

The latest national stroke audit data showed that only 54% patients with AF admitted with stroke between August 2016 and November 2016 were taking oral anticoagulants. Almost one-fifth of patients were taking antiplatelet therapy only, such as aspirin, despite it being removed from the NICE guideline and QOF more than a year ago. Edoxaban tosilate (Lixiana) 15mg film-coated tablets.

developing and updating local formularies-46

However, NICE concluded that they are cost-effective and should be made available in line with local guidance without additional funding or formulary restrictions.

CCGs should follow NICE recommendations, which state that warfarin or DOACs can be considered for newly diagnosed patients, patients inadequately managed with warfarin, and patients taking aspirin and thus should be made available locally.

There is also a wide variability in the use of DOACs across CCGs in England (see Figure 2). Use of direct oral anticoagulants (DOACs) across CCGs in England, 2016. One year on – Why are patients still having unnecessary AF-related strokes.

May 2016 Barriers to initiating oral anticoagulants for SPAF The perceptions of clinicians about risks associated with oral anticoagulants can be a barrier to the initiation of oral anticoagulation therapy.

This article discusses the barriers to the initiation of oral anticoagulants, in particular DOACs, and how these can be overcome.

Atrial fibrillation (AF) is the most common arrhythmia with over one million people diagnosed in the UK.

Their website also covers the recommendations of the NICE Good Practice Guidance on 'Developing and updating local formularies (GPG1).

To find out about local Lewisham CCG medicine guidelines go to the management of infection guidance document on the web site.

There is now a licensed specific reversal agent for dabigatran called idarucizumab Lack of experience is another key factor in preventing prescribing of oral anticoagulants for SPAF.

Tags: , ,